Nello is Founder, President, and Chief Executive Officer of Kymera Therapeutics. Under his leadership, Kymera has built a pipeline of multiple clinical stage, first-in-class degrader medicines; developed a best-in-class drug discovery platform; raised more than $1 billion of capital and formed strategic collaborations with major biopharmaceutical companies. Nello began his career at Novartis, leading cross-functional teams that identified several novel investigational medicines. Before founding Kymera, Nello was an Entrepreneur in Residence at Atlas Venture and previously led discovery research at Raze Therapeutics, a cancer metabolism startup. Nello studied at Imperial College, University of London and The Scripps Research Institute in California and has authored more than 80 publications and patents. He is passionate about helping teams achieve what has not been done before and scaling Kymera into a leading global biopharma company.

Prior to Kymera, Dr. Chadwick served as Senior Vice President, Head of Global Development Office at Takeda Pharmaceuticals. During his time there, his responsibilities included Head of Global Regulatory Affairs, as well as managing Global Drug Safety, Global Clinical Supply Chain and several groups supporting Global Development Operations. Before Takeda, Dr. Chadwick was Group Vice President and Head of Clinical Development Operations at Shire Pharmaceuticals. Earlier in his career, Dr. Chadwick held a number of senior development roles with broad responsibilities including program management, development operations, regulatory affairs, biostatistics and data management at The Medicines Company, Synta Pharmaceuticals, Vertex Pharmaceuticals and Glaxo Group Research. Dr. Chadwick has been involved in several successful global approvals spanning decades across multiple therapeutic areas. Dr. Chadwick previously served as chairman of the Board of Directors at Accumulus Synergy, a global organization developing a transformative data exchange platform designed to enhance how biopharmaceutical innovators and regulators bring safe and effective medicines to patients faster. He earned his MS and PhD in Statistics from the University of London and a BS in Mathematics from Demontfort University in the UK.

Prior to Kymera, Ellen served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Alexion Pharmaceuticals, where she was responsible for all legal, intellectual property and governance matters, and was the executive sponsor of the Corporate Social Responsibility program, until the company’s acquisition by AstraZeneca in 2021. In this role, she built and transformed the legal function, mission, and culture at the company by focusing on solutions, developing and mentoring talent, and implementing new technology and infrastructure. Before Alexion, Ellen was General Counsel at Alere, Inc., a point-of-care diagnostics company, where she spent over a decade managing various legal, government affairs, and governance functions through rapid growth and significant acquisitions globally. Earlier in her career, she was responsible for the legal function of the US neurology division at Serono and was a Partner at the law firm Hale and Dorr LLP.

Ellen currently serves as a member of the Board of Directors at Compass Therapeutics. She graduated magna cum laude from Bryn Mawr College and earned her Juris Doctor from Stanford University School of Law.

In his role as CMO, Jared leads clinical development for Kymera Therapeutics, advancing clinical candidates identified by Kymera’s proprietary Pegasus™ targeted protein degradation platform. Jared joined Kymera from Alnylam Pharmaceuticals, where he was Vice President of Clinical Development and Global Vice President of Medical Affairs for Amyloidosis. There, he led early and late stage clinical programs in infectious disease, oncology, and amyloidosis that provided the first proof of concept in humans for RNA interference therapeutics and culminated in the FDA and EMA approvals of ONPATTRO^TM for the treatment of hereditary transthyretin amyloidosis. Jared previously held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. He has authored more than 50 peer-reviewed papers published in top-tier medical and scientific journals. Jared received his BA and MD from Columbia University, and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.

As CFO, Bruce directs financial operations and investor relations for Kymera Therapeutics. Bruce joined Kymera with more than 25 years of experience in health care financial services, investment banking and equity research. He previously was Managing Partner for Westfield Capital Management, a Boston-based equity investment firm. In addition to his core portfolio management responsibilities, he served on the firm’s Management Committee and as the Health Care Team Lead. Bruce was also a Director with Alex Brown & Sons/Deutsche Bank and part of the health care investment banking group and the equity research team. He graduated magna cum laude from the Wharton School of the University of Pennsylvania, earned a Master of Business Administration from the Harvard Business School and is a Chartered Financial Analyst. Bruce is currently a member of the Board of Directors at Boys & Girls Clubs of Boston and serves on the Board of Advisors for Life Science Cares.

As Vice President, People and Culture, Karen brings more than 15 years of experience in human resources and operations, designing values-based initiatives to enhance company culture, improve employee experience and manage change in dynamic, innovative organizations in the biopharmaceutical industry. Prior to Kymera, she served in human resource leadership roles at bluebird bio, Inc., including building and leading the global People Partner function responsible for driving talent and organizational strategies with an emphasis on employee engagement, development, and performance.

Juliet is currently Head of Research at Kymera Therapeutics, where she is responsible for building the portfolio and delivering developmental candidates and INDs for the clinic. She has more than 20 years of drug discovery experience and has contributed to multiple INDs and medicines during her time at Novartis, Sanofi, Millennium, and Curis. Prior to Kymera, Juliet was the Head of Oncology Biology and Small Molecule Drug Discovery at Novartis Institutes for Biomedical Research in Cambridge and served in other leadership positions at both Novartis and Sanofi. Juliet holds a degree in Natural Sciences (Biochemistry) from the University of Cambridge and a PhD in Developmental Biology from University College London. Juliet subsequently completed a Wellcome Postdoctoral Fellowship at University College London in Developmental Biology.

As Senior Vice President, Head of Corporate Strategy at Kymera Therapeutics, Brian is responsible for the development and coordination of strategic initiatives that drive value creation and corporate growth. Brian joined Kymera from TESARO (now a GSK Company) where, as a Program Team Leader, he oversaw the FDA approval of the NK1RA rolapitant/Varubi IV and led multiple clinical programs in immuno-oncology, including the anti-PD-1 dostarlimab/Jemperli. While at TESARO, Brian also built and led the Competitive Intelligence function to support both clinical and commercial oncology programs, including the PARP inhibitor niraparib/Zejula. Brian was previously a strategy consultant at Leerink and Navigant Consulting after numerous biotech roles in process development, manufacturing, and business development at ICOS, Trubion Pharmaceuticals, and Emergent BioSolutions. Brian earned his MBA from the Wharton School of Business and holds a PhD in Bioengineering from the University of Washington and a BSE in Biomedical Engineering from Duke University.

As Senior Vice President, Corporate Affairs, Todd’s career has focused on developing and implementing integrated communications, advocacy and engagement strategies for life science companies. Before joining Kymera, Todd was Global Head of Science Communications at Sanofi, where he was responsible for strengthening the company’s scientific reputation, highlighting its pipeline and enhancing the culture of the R&D organization. Prior to Sanofi, Todd was Global Head of Brand and Science Communications at Biogen, where he led internal and external communications supporting Biogen’s marketed products, pipeline programs and R&D organization. At Biogen, he oversaw six product approvals, and generated awareness of the company’s academic, patient advocacy and industry collaborations and partnerships. Todd graduated from the University of Rochester with a B.A. in English.

As Vice President of Information Technology at Kymera Therapeutics, Kevin brings over 20 years of experience in information technology (IT) in the biopharmaceutical industry.  Kevin has extensive experience in planning, designing, and implementing innovative IT strategies and solutions to support growth across preclinical to commercial-stage organizations. Kevin previously held IT and operations leadership roles at Editas Medicine, Inc., Synageva Biopharma Corp., Zafgen, Inc., and Alnylam Pharmaceuticals. Kevin holds a Bachelor’s degree from the University of Massachusetts Amherst.

As Senior Vice President, Head of Development at Kymera Therapeutics, Ashwin is responsible for all phases of Kymera’s drug development programs.  Ashwin brings more than 20 years of drug development experience, including service at Pfizer Inc., Array BioPharma, Novartis AG, and Bristol-Myers Squibb Company (BMS). As Vice President of Clinical Science-Oncology at Array, Ashwin’s efforts led to successful filings of New Drug Applications for the targeted cancer therapies BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib). Ashwn has also held various leadership roles in clinical development and research at Pfizer, Novartis, and BMS. Ashwin holds a BA degree in Cell and Developmental Biology from Northwestern University and an MD from the University of Kansas School of Medicine. Ashwin subsequently trained in Internal Medicine and completed a Chief Residency at The Miriam Hospital-Brown University School of Medicine and in Medical Oncology at Yale University School of Medicine.

As SVP, Translational Medicine, Beccy joined Kymera to provide strategic oversight and tactical support for translational activities across all clinical stage and discovery programs. She has worked in the industry setting for more than 20 years. Prior to joining Kymera, she was Vice President of Translational Medicine at Mersana Therapeutics. She previously held positions of increasing responsibility in translational research and molecular pathology at Novartis, Vertex, and Millennium. Beccy graduated from Harvard College and received her MD from Columbia University. Her residency and fellowship training were in Anatomic and Clinical Pathology, and Cytopathology at Brigham and Women’s Hospital and Boston Medical Center. Before joining industry, Beccy practiced as a pathologist in the Boston area.

As Senior Vice President, Technical Operations, Vijay brings over 25 years of experience in the pharmaceutical and biotech industry, including over 10 years in senior leadership roles. Prior to joining Kymera, Vijay was Senior Vice President, Technical Operations at Theravance Biopharma where he was responsible for leading the process R&D, pharmaceutical development, analytical development, supply chain management and CMC project management functions. Vijay has extensive experience in drug development, regulatory interactions, and manufacturing. At Theravance, he led CMC efforts towards commercial approval of VIBATIV® and YUPELRI®, and partnership deals with several large pharma companies. Vijay holds a Bachelor’s Degree from the Indian Institute of Technology Madras, and a Master of Science from Rutgers, The State University of New Jersey, both in Chemical Engineering.

As Vice president, Quality, Jolly brings 25 years in quality oversight of manufacturing and clinical trial lifecycle activities including process and product development, clinical and commercial supply chains and new product launch. Prior to Kymera, he served in quality leadership roles at X4 Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Genzyme Corporation. He holds a Bachelor of Pharmacy degree from Birla Institute of Technology and Science and a Master’s degree in Industrial Pharmacy from St. John’s University.

As Vice President, Business Development, Melissa brings nearly a decade of experience in the biotechnology industry advising biopharma companies on strategic transactions. Prior to Kymera, Melissa was a Principal at Aquilo Partners, a boutique life sciences investment bank, where she was responsible for leading the execution of collaborations, licensing transactions, private placements, and mergers and acquisitions across a variety of therapeutic areas, including Kymera in its collaboration with Sanofi, Disarm in its sale to Lilly, and Protomer in its sale to Lilly. Melissa earned her Bachelor’s in Biology and Ecology (Phi Beta Kappa) from the University of Georgia, where she also played on the Georgia Bulldogs NCAA Division I Women’s Varsity Golf team.

Ms. Koenigsberg has more than 25 years of investor relations and corporate communications experience within the biotechnology industry. Before joining Kymera, she served as Senior Vice President, Corporate Communications and Investor Relations at Concert Pharmaceuticals, Inc. Prior to joining Concert, she held senior communication roles at ViaCell, Inc. and Transkaryotic Therapies, Inc. (TKT) where she developed and implemented a variety of communication strategies and managed their investor relations programs. Before TKT, she held communications positions at Vertex Pharmaceuticals, Inc. Ms. Koenigsberg is a member of the National Investors Relations Institute and served on the Board of Directors and as a Past-President of its Boston Chapter. She holds a B.S. in Business Administration from Northeastern University.

As Head of Regulatory Affairs, Aimee is responsible for oversight and management of the Regulatory Affairs function at Kymera, including nonclinical, CMC and clinical regulatory strategies for all Kymera development candidates. Aimee has over 15 years of regulatory affairs experience in the biotechnology industry, serving as the lead regulatory strategist for several commercially successful medicines. Before joining Kymera, Aimee gained significant experience in small and midsized companies, with increasing levels of responsibility and leadership roles through her tenure at Forma Therapeutics, Clovis Oncology, Array BioPharma and OSI Pharmaceuticals. She has supported early and late-stage drug development programs in multiple therapeutic areas and has extensive experience in biotech-pharma co-development partnerships, regulatory intelligence research and due diligence, as well as clinical development plan execution. Aimee is a passionate patient advocate in her personal and professional lives with a focus on oncology patient engagement and advocacy and patient-focused drug development. She holds a B.S. in  Molecular, Cell and Developmental Biology and a B.A in English Literature from the University of Colorado, and an M.S. in Pharmacology and Toxicology from Michigan State University.

Aimee also serves as the Program Team Leader of Kymera’s IRAKiMID program, KT-413, currently under development for MYD88-mutant Diffuse large B-cell lymphoma, or DLBCL.

As Vice President, Immunology at Kymera Therapeutics, Anthony leads the Immunology team at Kymera Therapeutics and brings deep research and development experience in both small molecule and biologic drug discovery. He has been involved in multiple aspects of drug discovery and development in pharmaceutical and biotechnology companies in the U.S. for more than 20 years, leading discovery, and pharmacology teams, as well as being involved in efforts focused on the external identification and diligence of novel technologies and assets suitable for in-licensing and/or acquisition. Prior to joining Kymera, Anthony held leadership positions in Immunology at Abbvie and Boehringer Ingelheim, where he oversaw research departments dedicated to identifying and developing therapeutics for grievous autoimmune diseases, including the recently approved SKYRIZI, a monoclonal antibody targeting IL-23. He started his career at Tularik which was acquired by Amgen, and was a group leader at the Genomics Institute of the Novartis Research Foundation (GNF). Anthony holds a BSc (Hons.) and a PhD degree from the University of Melbourne and trained as a research fellow at Harvard Medical School and Stanford University.